Form 4: Boston Scientific Exec Rebalances 401(k) Holdings

Boston Scientific's EVP & Group President, Arthur C. Butcher, rebalanced his 401(k) holdings, acquiring 6,851 shares of common stock at $75.76 and disposing of 55,792 shares.

Summary

• Arthur C. Butcher, EVP & Group President, MedSurg & APAC at Boston Scientific Corp (BSX), reported changes in his beneficial ownership.
• On February 19, 2026, Mr. Butcher acquired 6,851 shares of common stock indirectly through the company's 401(k) Retirement Savings Plan at a price of $75.76 per share.
• This acquisition was part of an election to rebalance his holdings within the 401(k) plan.
• Concurrently, 55,792 shares of common stock were disposed of, also likely as part of the 401(k) rebalancing.
• Following these transactions, Mr. Butcher beneficially owns 20,205 shares of common stock indirectly via his 401(k) plan.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While there's a net disposition of shares from the 401(k), it's part of a pre-planned rebalancing, which is a routine personal financial decision rather than a signal of management's view on the company's immediate prospects.

Positives

• The acquisition of 6,851 shares at $75.76, even as part of a rebalancing, indicates continued investment in company stock by a key executive.
• The transaction was pre-planned under a Rule 10b5-1(c) plan, suggesting a structured approach to insider trading compliance.

Negatives

• A significant disposition of 55,792 shares occurred, which, while part of a rebalancing, represents a net decrease in the executive's overall holdings within the 401(k) plan.
• The net beneficial ownership in the 401(k) after the rebalancing is 20,205 shares, indicating a substantial reduction from the implied pre-rebalancing 401(k) holding of 69,146 shares (20,205 + 55,792 6,851).

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance; it reports a pre-planned transaction.

Management Comments

• Acquisition made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.
• Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving rebalancing within retirement plans, are common. While the disposition of a larger number of shares might raise questions, the 10b5-1 plan indicates a pre-scheduled, non-discretionary nature at the time of the transaction, which is a standard practice for executives to manage their holdings while avoiding accusations of trading on material non-public information.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan for executive stock transactions is a standard corporate governance practice among publicly traded companies, including peers in the medical device industry like Medtronic (MDT) or Abbott Laboratories (ABT), to manage insider trading compliance.
• Rebalancing within a 401(k) plan is a common personal financial management strategy, not unique to Boston Scientific or its executives.

Stakeholder Impact

• Shareholders: The transaction itself is unlikely to have a significant direct impact on shareholders, as it's a personal financial decision by an executive. However, large insider dispositions can sometimes be viewed negatively if not properly contextualized.
• Employees: No direct impact on employees is indicated.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-planned rebalancing of an executive's 401(k) holdings, resulting in a net disposition of shares from that specific account. While the disposition is notable in quantity, its nature as a rebalancing under a 10b5-1 plan suggests it's a personal financial management decision rather than a reflection of the executive's immediate outlook on the company's performance. Therefore, it does not provide sufficient new information to warrant a change in investment thesis, leading to a "hold" recommendation.

Keywords

Boston Scientific, BSX, Form 4, Insider Trading, Stock Transaction, Executive Compensation, 401(k) Rebalancing, Arthur C. Butcher, Equity Holdings, Rule 10b5-1